'Washington Black': Why Sterling K. Brown, Tom Ellis, Ernest Kingsley Jr. show had to film in Halifax
"I think what made the novel such an effective piece of work is that it has a core emotional DNA that's universal," creator, co-showrunner and executive producer, Selwyn Seyfu Hinds, told Yahoo Canada. "People are always thinking about how to write a story that appeals to everyone, that gets to everyone, and I always say that you find universality in specificity."
"There's something, sure, that starts in a very specific place about Wash and his challenges and his journey, the way he finds light out of darkness. But as you move that micro out to macro, that's all of us. ... We're all looking for that light at the end of the tunnel."
Set in the 19th century, Wash develops an interest in science at a young age (first played by Eddie Karanja, later Ernest Kingsley Jr.), with inventor Christopher 'Titch' Wilde (Tom Ellis) taking him under his wing, becoming a mentor for Wash as they team up to create inventions, including a flying machine.
In the later timeline Wash is living as a free man in Halifax, quickly crushing on Tanna Goff (Iola Evans), born on the Solomon Islands and raised by her white father, played by Rupert Graves, after her mother's death when she was young.
"[They're both] discovering who they are, who you are told to be, versus who you feel you are inside," co-showrunner and executive producer, Kimberly Ann Harrison, said. "I think that we were able to explore that through [Tanna], in a different way."
"The stories really kind of mirrored each other, ... just through the female lens. I really think that was important, to ... be able to platform her story and show her struggle with identity. And eventually, stepping into her own shoes of what she wants."
Throughout the show's eight episodes, the audience is taken on a globe-trotting adventure through Wash's life.
"We have lots of influences, but I have two really big ones. One on the literary side is Jules Verne. ... And the other one, as a kid in the '70s and the '80s, is Spielberg," Hinds said.
"So in some ways Wash is sort of like those two worlds for me mashing together. And it was just a thrill to be able to find a project that allowed you to do that."
View this post on Instagram
A post shared by Disney+ Canada 🇨🇦 (@disneyplusca)
There's something particularly compelling, unique and appealing about how Washington Black tells the story from a child's point of view, with Hinds highlighting that "children dream of the impossible."
"I think putting the story in a child's eyes gives you access to a kind of imagination, a kind of dreaming, just a kind of emotional resiliency that's different with an adult character," he said.
Additionally, there's a n impactful exploration of how Wash is impacted by the mentors in his life, but they learn from him as well.
"I think there's a lot that obviously Wash learned from his mentors, both in the past and present day, but at the same time a lot of these adults are learning life lessons from this child, from this enslaved child," Harrison said. "That's what really is special about this series."
Filming in Halifax: 'We couldn't have faked this anywhere else'
In order to have the authenticity required to effectively tell this story, Washington Black had to be filmed in Nova Scotia, while the crew behind the film also comitted to connecting with the local community.
"Authenticity is a word that we toss around a lot, and community. Even before we started rolling cameras in Halifax, we were there for months on the ground, just in pre-production," Hinds explained. "And during that time, were able to learn so much more about the history, learn so much more about the community, and go into the [Black Loyalist Heritage Centre] in Halifax. It was just an overwhelming, emotional experience, ... talking to people whose families have been there for hundreds of years."
"So we really try to infuse the real place into the show, and that's part of ... the effect it has when you watch it."
"We couldn't have faked this anywhere else," Harrison added. "This entire time in Halifax was a history lesson for me, in particular, and I just think that's what made it so special. And being authentic to the location and telling that story, I just think that's what brought it all together."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025
NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced results showing that implementing a blood-based pTau217 screening assay reduced Acumen's overall clinical trial screening costs by approximately 40% in its Phase 2 ALTITUDE-AD study of sabirnetug in early Alzheimer's disease in the U.S. and Canada. Additionally, a nonclinical study revealed sabirnetug achieved the highest selectivity for AβOs over Aβ monomers relative to recombinant lecanemab and aducanumab. The results are being presented at the Alzheimer's Association International Conference (AAIC), taking place July 27-31, 2025, in Toronto and online. 'These advances represent important progress in addressing the critical need for effective treatments targeting toxic amyloid β oligomers (AβOs) in early symptomatic Alzheimer's disease, while simultaneously demonstrating patient-centric and cost-effective trial execution strategies,' said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. 'By combining cutting-edge therapeutic development with smart clinical trial strategies, we're working to create a more efficient path forward in bringing potential new options to patients with Alzheimer's disease. " ALTITUDE-AD: Cost savings using a pTau217 screening assay in an ongoing Phase 2 study of sabirnetug in early Alzheimer's disease Acumen reported operational innovations in its ALTITUDE-AD Phase 2 clinical trial where researchers implemented an innovative two-step screening process using plasma pTau217 biomarker assay testing that yielded significant clinical trial screening and cost efficiencies. The approach reduced total screening costs by approximately 40% across U.S. and Canadian sites. Furthermore, the screening process was efficient, with 48% of participants meeting the pTau217 threshold required for confirmatory testing. Among those who passed this initial screening, 81% of participants successfully met amyloid positivity eligibility requirements. The strategy performed as intended, helping to achieve strong enrollment rates and reducing unnecessary amyloid PET scans and lumbar puncture procedures for potential participants. Sabirnetug shows superior selectivity for Aβ oligomers over monomer, a differentiated mechanism of action. Soluble, synaptotoxic AβOs are an early and persistent driver of AD-related pathophysiology and represent a key target for the development of next-generation therapies for Alzheimer's disease. Targeting soluble AβOs may slow down neurodegeneration, reduce tau hyperphosphorylation, and prevent synapse loss for patients with early AD. Acumen demonstrated sabirnetug's selectivity for binding to toxic AβOs through comprehensive surface plasmon resonance testing. The study revealed sabirnetug achieved the highest binding affinities to AβO preparations among the monoclonal antibodies tested. Sabirnetug also showed minimal interaction with monomeric Aβ, which is significant given that monomeric forms are approximately 7,000-fold more abundant than oligomers in the cerebrospinal fluid of patients with MCI and mild dementia due to AD. Overall, sabirnetug demonstrated 8,750-fold selectivity for Aβ1-42 stabilized oligomers over Aβ1-40 monomers. The results support sabirnetug's mechanism of action and selectivity for AβOs. About Sabirnetug (ACU193) Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer's disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD. About ALTITUDE-AD (Phase 2) Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer's disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. More information can be found on NCT identifier NCT06335173. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as 'potential,' 'will' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the therapeutic potential and potential clinical efficacy of Acumen's product candidate, sabirnetug (ACU193) and the efficiencies and costs associated with the pTau217 screening assay. These statements are based upon the current beliefs and expectations of Acumen's management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ('SEC'), including in Acumen's most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. Investors:Alex Braunabraun@ Media:Jon YuICR HealthcareAcumenPR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation
Highly selective targeting in Tg AD mouse model improved short-term memory and reduced plaque burden SEATTLE, July 28, 2025--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases will today present new preclinical data at the Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada, reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer's disease (AD). "We are thrilled to showcase these exciting preclinical results for our SOBIN-AD therapeutic," said Valerie Daggett, Ph.D., CEO and Founder of AltPep. "Our compound is based on the discovery that toxic oligomers, early triggers for amyloid diseases such as AD, form a nonstandard protein structure called α-sheet. We have now demonstrated that SOBIN-AD not only selectively targets the α-sheet toxic oligomers but also enhances clearance of these toxic oligomers." Carolyn Tallon, Ph.D., Principal Scientist, who will present the AltPep data at AAIC, further commented, "Importantly, we showed that SOBIN-AD treatment improved short-term memory and reduced plaque burden in Tg AD mice, after 6 and 12 months of dosing, respectively. These exciting data mark a major milestone for SOBIN-AD and bring hope for early treatment of AD." Poster Presentation Details: Title: Designed peptide increases clearance of Aβ toxic oligomers and inhibits plaque formationPoster #: 104011Date / Time: Monday, July 28, 2025: 7:30 AM – 4:15 PM EDTLocation: Exhibit Hall DE The poster will also be available in the "Scientific Publications" section of the AltPep website under "Presentations" at Select preclinical data show SOBIN-AD: binds Aβ oligomers 27,000-fold stronger than protofibrils; enhances microglial phagocytosis of toxic Aβ oligomers in a dose-dependent manner; significantly improves short-term memory in 9-month old Tg2576 AD mice after 6 months of dosing, 3X/week intranasally; and significantly reduces AB plaque burden in 15-month-old AD mice after 12 months of dosing, 3X/week intranasally. Gil Block, M.D, Ph.D., and Chief Medical Officer of AltPep remarked, "These results compellingly support the promise of SOBIN-AD as a transformative early treatment option for patients with AD. This achievement is especially important as we advance our program towards the clinic." About AltPep CorporationAltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression. AltPep's emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer's and Parkinson's diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep's goal is to change the course of these debilitating diseases that affect over a billion people around the globe. Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep's innovative approach. About SOBIN Therapeutics and SOBA DiagnosticsSOBIN therapeutics are in development for use in concert with early detection tools to target and neutralize the toxic soluble oligomers associated with amyloid diseases. SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases. For more information, please visit and follow us on LinkedIn. View source version on Contacts Media Contact: Susan SharpeLinnden Communicationssusan@

Miami Herald
6 hours ago
- Miami Herald
Greg Cote Show: Greg from Canada, Happy Gilmore 2, Kurkjian more
Chris and Yeti take the lead on the Greg Cote Show's newest Episode #281, out now, while Greg is away on vacation in Canada. But then Greg either saves the day or ruins everything (depending on one's perspective) by barreling into the show from Capilano Suspension Bridge Park in Vancouver. Learn about Greg's visit to the secret (or at least unmarked) Prophecy bar in Vancouver; how many times Greg's wife awkwardly engaged Canadians about U.S. politics; a hockey conversation in a mountain-climbing gondola; and a lovely unexpected visit with huge fans of ours who noticed us at Fanny Bay Oyster Bar. Plus new Dad Jokes and special Canada-edition of Three Facts, Jack! Almost forgot: My immunity to travel-induced constipation, and a related new superhero nickname. This is our 281st episode overall and 30th of 2025 and we welcome you back as always. Also on the latest show: ▪ ESPN baseball maven Tim Kurkjian weighs in as we explore the baseball colloaquialism, 'hind catcher.' ▪ A (surprising) review of the new Happy Gilmore 2 sequel. ▪ Ozzy Osbourne's perfect exit. ▪ Greg's negative encounter with Hulk Hogan. ▪ Wait, is Chris hosting a new Dolphins podcast!? ▪ McDonald's Migraine Hack. ▪ Yeti shares secrets about fast food, what annoys him about his church congregation and more. There's all of this and more in our new GCS #281. Aside from occasional bonus episodes, a new show drops every Monday morning at 7 on Apple Podcasts, Spotify — wherever you pod, including at Find our entire show catalog with all 281 episodes HERE. (We also simulcast on Sirius XM radio Mondays from 5 to 6 p.m.) Our podcast debuted in March 2020 just as the pandemic hit. (Coincidence; don't blame us). We thank you all, our pod family, for your great and growing support. Please continue to listen, rate, review, subscribe (it's free) and tell all your friends and family, too! Also check us out at The Greg Cote Show on YouTube — the channel is spankin' new and improved! And follow @TheGregCoteShow on it's-still-Twitter-to-me. Also visit website and click 'Shop' for our merch store, including a variety of fresh designs. Shoppin' It.